Lung cancer overview
This resource will cover guideline-recommended testing from AMP, ASCO, CAP (College of American Pathologists), and IASLC (International Association for the Study of Lung Cancer), as well as how these organizations direct biomarker-informed treatment, with recommendations on IO (immuno-oncology), NGS, PCR (polymerase chain reaction), and other testing modalities.
Sample requirements and testing approaches in mNSCLC
In mNSCLC, small tissue biopsies can present challenges to comprehensive biomarker testing. In this resource, see how processes such as ROSE and reflex testing, and technologies including NGS and liquid biopsy, can optimize the tissue testing journey.1-4
References
- Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647–1662.
- Tsimberidou AM, Sireci A, Dumanois R, et al. Strategies to address the clinical practice gaps affecting the implementation of personalized medicine in cancer care. JCO Oncol Pract. 2024;20(6):761–766.
- Yu TM, Morrison C, Gold EJ, et al. Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of Oncomine Dx Target Test for advanced non-small-cell lung cancer: a single center analysis. Clin Lung Cancer. 2019;20(1):20–29.e8. doi: 10.1016/j.cllc.2018.08.010
- Garcia-Pardo M, Czarnecka-Kujawa K, Law JG, et al. Association of circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial. JAMA Netw Open. 2023;6(7):e2325332. doi: 10.1001/jamanetowrkopen.2023.25332